2021
Renal sarcomas: Epidemiology, treatment and outcomes.
Uhlig J, Uhlig A, Deshpande H, Hurwitz M, Humphrey P, Kim K. Renal sarcomas: Epidemiology, treatment and outcomes. Journal Of Clinical Oncology 2021, 39: 362-362. DOI: 10.1200/jco.2021.39.6_suppl.362.Peer-Reviewed Original ResearchPrimitive neuroectodermal tumorRenal sarcomaOverall survivalMalignant rhabdoid tumorSEER databaseSurgical resectionSystemic therapyDistant metastasisTumor diameterSarcoma subtypesIncidence rateRenal malignancyAge-adjusted incidence ratesCox proportional hazards modelMedian tumor diameterAdvanced T stageDifferent histological subtypesProportional hazards modelSolitary fibrous tumorWorse OSAdult patientsFemale predominanceMale predominanceMedian ageOS rates
2020
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy